Dr. Martens's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 31.05.
Dr. Martens's Days Inventory for the
six
months ended in Mar. 2026 was 223.54.
Dr. Martens's Days Payable for the
six
months ended in Mar. 2026 was 101.11.
Therefore, Dr. Martens's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 153.48.
Dr. Martens (CHIX:DOCSl) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Dr. Martens Cash Conversion Cycle Related Terms
Dr. Martens Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Dr. Martens's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DOCSL vs NKE, DECK, ONON: Cash Conversion Cycle Comparison
For the Footwear & Accessories subindustry, Dr. Martens's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Martens Cash Conversion Cycle vs Manufacturing - Apparel & Accessories Industry
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Dr. Martens's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Dr. Martens's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Dr. Martens's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Martens (CHIX:DOCSL) has a Cash Conversion Cycle of 153.48 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Dr. Martens and its competitors.
Is Dr. Martens' Cash Conversion Cycle too high?
Dr. Martens' current Cash Conversion Cycle is 153.48. The Manufacturing - Apparel & Accessories industry median Cash Conversion Cycle is 124.38. Dr. Martens' value of 153.48 is 23.4% above this industry median. Overall, Dr. Martens has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Martens' Cash Conversion Cycle compare to NKE and DECK?
Dr. Martens' Cash Conversion Cycle of 153.48 can be compared against companies in the Manufacturing - Apparel & Accessories industry. The industry median Cash Conversion Cycle is 124.38. Dr. Martens' value of 153.48 is 23.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Manufacturing - Apparel & Accessories company?
The median Cash Conversion Cycle among Manufacturing - Apparel & Accessories companies is 124.38, based on 1,041 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Martens's current Cash Conversion Cycle of 153.48 is 23.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Dr. Martens and its competitors. For the Manufacturing - Apparel & Accessories industry, the median Cash Conversion Cycle is 124.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Martens's current Cash Conversion Cycle is 153.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Martens stock overvalued right now?
Based on GuruFocus' analysis, Dr. Martens (CHIX:DOCSL) is currently considered Fairly Valued. The stock's GF Value™ is £0.72, compared to a current price of £0.70 — trading 2.5% below its estimated fair value. The current Cash Conversion Cycle is 153.48 and 23.4% above the Manufacturing - Apparel & Accessories industry median of 124.38. Dr. Martens' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Dr. Martens (CHIX:DOCSL), the current Cash Conversion Cycle is 153.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Martens (CHIX:DOCSL) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Martens stock appears to be undervalued.
The current stock price of £0.70 is trading 2.5% below its estimated GF Value™ of £0.72.
GuruFocus considers Dr. Martens to be Fairly Valued.
Key valuation signals for CHIX:DOCSL:
Cash Conversion Cycle: 153.48
GF Value™: £0.72 vs. price of £0.70 (2.5% below fair value)
Industry Position: 23.4% above the Manufacturing - Apparel & Accessories median
No single metric tells the full story. See the CHIX:DOCSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Martens PLC is engaged in the footwear business. Its product segments include Originals, Fusion, Kids and Casual, and a complementary range of Accessories. The company has sales through E-commerce, Retail, and Wholesale of Products. Geographically, it derives the majority of its revenue from EMEA and has a presence in the Americas and APAC.
52GF Score
Get the complete analysis for CHIX:DOCSL
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DOCSL has been successfully added to your 
